We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01349361
Recruitment Status : Unknown
Verified March 2011 by Bispebjerg Hospital.
Recruitment status was:  Recruiting
First Posted : May 6, 2011
Last Update Posted : May 6, 2011
Sponsor:
Information provided by:

Study Description
Brief Summary:
Photodynamic Therapy (PDT) is an effective treatment of basal cell carcinomas (BCC) however the inconvenience of clinic attendance and discomfort during therapy are significant drawbacks. The objective of this study is to evaluate the effect of daylight-mediated PDT of BCC.

Condition or disease Intervention/treatment Phase
Photodynamic Therapy Basal Cell Carcinomas Procedure: Daylight mediated photodynamic therapy Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Official Title: Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight
Study Start Date : March 2011
Estimated Primary Completion Date : January 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Daylight-PDT Procedure: Daylight mediated photodynamic therapy


Outcome Measures

Primary Outcome Measures :
  1. complete disappearance of the BCC

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • superficial BCC

Exclusion Criteria:

  • Immunosuppression
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01349361


Contacts
Contact: Stine R Wiegell, MD, PhD swie0001@bbh.regionh.dk

Locations
Denmark
Bispebjerg Hospital Recruiting
Copenhagen NV, Denmark, 2400
Contact: Stine R Wiegell, MD, PhD       swie0001@bbh.regionh.dk   
Principal Investigator: Stine R Wiegell, MD, PhD         
Sponsors and Collaborators
Bispebjerg Hospital
More Information

Responsible Party: Hans Christian Wulf, Bispebjerg Hospital
ClinicalTrials.gov Identifier: NCT01349361     History of Changes
Other Study ID Numbers: 2010-024517-31
First Posted: May 6, 2011    Key Record Dates
Last Update Posted: May 6, 2011
Last Verified: March 2011

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Basal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Basal Cell
Aminolevulinic Acid
Methyl 5-aminolevulinate
Photosensitizing Agents
Dermatologic Agents